Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study-Reference-Cited by-同舟云学术

Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study

Published:2023-06-28 Issue:14 Volume:24 Page:1649-1656
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Tursi Antonio¹²,Mocci Giammarco³,Cingolani Linda³,Savarino Edoardo³,Pica Roberta⁴,Cocco Andrea⁴,Zippi Maddalena⁴,Napolitano Daniele⁵,Schiavoni Elisa⁵,Pugliese Daniela⁵⁶,Scaldaferri Franco⁵⁶,Costa Francesco⁷,Marzo Manuela⁸,Serio Mariaelena⁹,Scarcelli Antonella⁹,Bolognini Laura¹⁰,Bendia Emanuele¹⁰,Maconi Giovanni¹¹,Cannatelli Rosanna¹¹,Piergallini Simona¹²,Bodini Giorgia¹³,Calabrese Francesco¹³,Ferronato Antonio¹⁴,Pranzo Giuseppe¹⁵,Elisei Walter¹⁶,Monterubbianesi Rita¹⁶,Faggiani Roberto¹⁶,Rodinò Stefano¹⁷,Sebkova Ladislava¹⁷,Grossi Laurino¹⁸,Gaiani Federica¹⁹,dè Angelis Gianluigi¹⁹,Lorenzetti Roberto²⁰,Allegretta Leonardo²¹,Cazzato Alessia Immacolata²¹,Scorza Stefano²¹,Della Valle Nicola²²,Sacco Rodolfo²²,Forti Giacomo²³,Colucci Raffaele²⁴,Tonti Paolo²⁵,Neve Viviana²⁵,Rocco Giulia²⁶,Sacchi Carlotta²⁶,Zampaletta Costantino²⁶,Pagnini Cristiano²⁷,Graziani Maria Giovanna²⁷,Di Paolo Maria Carla²⁷,Onidi Francesca Maria²⁸,Usai Satta Paolo²⁸,Picchio Marcello²⁹,Papa Alfredo⁵⁶

Affiliation:

1. Territorial Gastroenterology Service, Asl Bat, Andria, Italy

2. Department of Medical and Surgical Sciences, Catholic University, Rome, Italy

3. Gastroenterology Unit, Azienda Ospedale-Università di Padova (AOUP), Padua, Italy

4. Division of Gastroenterology, IBD Unit, “S. Pertini” Hospital, Rome, Italy

5. CEMAD (Digestive Disease Center), Department of Medical and Surgical Sciences, Policlinico Universitario “A. Gemelli” IRCCS Foundation, Rome, Italy

6. School of Medicine, Catholic University, Rome, Italy

7. IBD Unit, Department of General Surgery and Gastroenterology, Pisa University Hospital, Pisa, Italy

8. Division of Gastroenterology, “Veris-Delli Ponti” Hospital, Scorrano (LE), Italy

9. Division of Gastroenterology, “San Salvatore” Hospital, Pesaro, Italy

10. Division of Digestive Diseases, Digestive Endoscopy and Inflammatory Bowel Diseases, Ancona, Italy

11. Division of Gastroenterology, “L. Sacco” University Hospital, Milan, Italy

12. Division of Gastroenterology, IBD Unit, “A. Murri” Hospital, Fermo, Italy

13. Department of Internal Medicine and Medical Specialties, Division of Gastroenterology, IRCCS “San Martino” Hospital, University of Genoa, Genoa, Italy

14. Digestive Endoscopy Unit, Santorso, VI, Italy

15. Ambulatory for IBD Treatment, “Valle D’Itria” Hospital, Martina Franca (TA), Italy

16. Division of Gastroenterology, ”S. Camillo-Forlanini” Hospital, Rome, Italy

17. Division of Gastroenterology, “Ciaccio-Pugliese” Hospital, Catanzaro, Italy

18. Gastroenterology Unit, “Spirito Santo” Hospital, “G d’Annunzio” University, Pescara, Italy

19. Gastroenterology and Endoscopy Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy

20. Division of Gastroenterology, “Nuovo Regina Margherita” Territorial Hospital, Rome, Italy

21. Division of Gastroenterology, “Santa Caterina Novella” Hospital, Galatina (LE), Italy

22. Division of Gastroenterology, A.O. “Ospedali Riuniti”, Foggia, Italy

23. Division of Digestive Endoscopy, “S. Maria Goretti” Hospital, Latina, Italy

24. Digestive Endoscopy Unit, “San Matteo Degli Infermi” Hospital, Spoleto (PG), Italy

25. Division of Gastroenterology, “A. Perrino” Hospital, Brindisi, Italy

26. Division of Gastroenterology, “Belcolle” Hospital, Viterbo, Italy

27. Division of Gastroenterology, “S. Giovanni - Addolorata” Hospital, Rome, Italy

28. Division of Gastroenterology, “Brotzu” Hospital, Cagliari, Italy

29. Division of General Surgery, “P. Colombo” Hospital, ASL Roma 6, Velletri (Roma), Italy

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2023.2230126

Reference28 articles.

1. What is the future of targeted therapy in rheumatology: biologics or small molecules?

2. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

3. Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open‐label, long‐term extension study with up to 7.0 years of treatment

4. Real-World Experience with Tofacitinib in IBD at a Tertiary Center

5. Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Remission of refractory esophageal lichen planus induced by tofacitinib;Zeitschrift für Gastroenterologie;2024-06-25

2. Effect of Tofacitinib on One-Year Colectomy Risk in Anti-TNF Refractory Ulcerative Colitis: A Prospective Multicenter Italian Study;Digestive Diseases and Sciences;2024-03-26

3. Tofacitinib real-world experience in ulcerative colitis in Finland (FinTofUC): a retrospective non-interventional multicenter patient chart data study;Scandinavian Journal of Gastroenterology;2023-12-29